CLIENT LOGIN

USER NAME

PASSWORD

SUBMIT

RECENT NEWS
2007

• »
  Arrow Therapeutics Acquired by AstraZeneca
• »
  Bob Ai Returns to Merlin Nexus

2006

• »
  Affymax Stages Successful IPO
• »
  Confluent Surgical
  Acquired by U.S. Surgical
• »
  Cougar Biotechnology Goes Public
• »
  AGI Therapeutics Raises €42.5 Million in Public Offering

The Merlin Nexus objective is to realize long-term capital appreciation from investments in:

• Late-stage private companies
• PIPEs (Private Investments in Public Equity)
• Select long-term open market investments

Our crossover strategy enables us to take advantage of valuation disparities between the private and public markets. In the life sciences industry, there are opportunities to participate in multiple financings at various stages of development.

Merlin Nexus Funds invest in growth segments of the healthcare industry, with an emphasis on product-driven life sciences companies developing breakthrough therapeutics for clinical needs, positively altering disease course and associated costs.

Unlike venture capital funds, Merlin Nexus funds are distinguished by relatively high liquidity and by short 5-year maturity. We target for each private investment, a potential for liquidity within 24 months after initial investment, as well as a 2-3 times return on invested capital.

We communicate frequently with management of our portfolio companies, taking an active role in ongoing investment management, though we steer clear of actual governance. We add value by extremely diligent, clinically-focused, “forensic” due diligence.